NCT05434663View on ClinicalTrials.gov

Safety Study of Repeat Doses of SUSTOL in Adults

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Chemotherapy-Induced Nausea and Vomiting (CINV)

Interventions

DRUG

SUSTOL

SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles.

Trial Locations (2)

29401

Hattiesburg Clinic Hematology/Oncology, Hattiesburg

44718

Gabrail Cancer Center Research, Canton

Sponsors

Lead Sponsor

Heron Therapeutics

All Listed Sponsors

lead

Heron Therapeutics

INDUSTRY